About Urteste

Urteste specialises in the development of an innovative technology allowing the detection of cancers at early stages of their development. The Urteste motto is: Early cancer detection saves lives. The company’s ground-breaking technology helps detect cancers by measuring the activity of the enzymes in urine. Urteste develops diagnostic tests for more than ten of the most common cancers. The company’s team consists of managers with wide experience in leading medical companies and scientists who specialise in the area of proteolytic enzymes and peptide chemistry.


Our vision is to create a technology that detects many cancer conditions at early enough stages of their development. Early cancer detection increases the chances of effective treatment.

Project description

Cancer can develop over a period of more than ten years without showing any warning signs. Global screening tests are currently only available for several cancer types. These mainly involve imaging tests (RTG, USG). The majority of patients are thus diagnosed too late.

Source: WHO – Guide to cancer early diagnosis

Late diagnosis has a very negative effect on the development of the cancer and reduces the chances of effective treatment. For example, only 1% of patients with pancreatic cancer live for 5 years following diagnosis. When diagnosed early, pancreatic cancer can be treated surgically.

Urteste is developing ground-breaking technology for detecting cancers by measuring the activity of the enzymes in urine. The purpose of the technology is to detect multiple cancers at an early stage, using a single urine sample. The company is currently developing tests intended to detect more than ten of the most common cancers: (pancreatic, prostate, kidney, colorectal, liver, bile duct, stomach, lung, throat, ovary, uterus, blood and nervous system cancer).

Market leverage of the Urteste technology

  • Previous tests indicate high parameters in terms of test sensitivity and specificity. One urine sample can help detect many types of cancers.
  • The test is non-invasive (urine sample test) – safe and convenient for patients.
  • The test result is available in approximately 2 hours.
  • Low test cost – does not require highly skilled personnel or expensive laboratory equipment.
  • Interpretation of the result is simple and unambiguous.

High demand for cancer diagnostic tests – cancers are the second leading cause of death globally.